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Abstract
Background: Modern cancer research often involves large datasets and the use of sophisticated statistical
techniques. Together these add a heavy computational load to the analysis, which is often coupled with issues
surrounding data accessibility. Connectivity mapping is an advanced bioinformatic and computational technique
dedicated to therapeutics discovery and drug re-purposing around differential gene expression analysis. On a normal
desktop PC, it is common for the connectivity mapping task with a single gene signature to take > 2h to complete
using sscMap, a popular Java application that runs on standard CPUs (Central Processing Units). Here, we describe
new software, cudaMap, which has been implemented using CUDA C/C++ to harness the computational power of
NVIDIA GPUs (Graphics Processing Units) to greatly reduce processing times for connectivity mapping.
Results: cudaMap can identify candidate therapeutics from the same signature in just over thirty seconds when
using an NVIDIA Tesla C2050 GPU. Results from the analysis of multiple gene signatures, which would previously have
taken several days, can now be obtained in as little as 10 minutes, greatly facilitating candidate therapeutics discovery
with high throughput. We are able to demonstrate dramatic speed differentials between GPU assisted performance
and CPU executions as the computational load increases for high accuracy evaluation of statistical significance.
Conclusion: Emerging ‘omics’ technologies are constantly increasing the volume of data and information to be
processed in all areas of biomedical research. Embracing themulticore functionality of GPUs represents a major avenue
of local accelerated computing. cudaMap will make a strong contribution in the discovery of candidate therapeutics
by enabling speedy execution of heavy duty connectivity mapping tasks, which are increasingly required in modern
cancer research. cudaMap is open source and can be freely downloaded from http://purl.oclc.org/NET/cudaMap.
Background
Cancer research is becoming extremely high throughput,
using modern methods from microarray to next genera-
tion sequencing, where thousands of counts of biological
entities are collected in order to address complicated bio-
logical questions. Gene expression connectivity mapping
is a powerful bioinformatic technique for establishing the
connections among genes, drugs and diseases [1]. There
are three key components in the connectivity mapping
process: a gene signature representing the biological state
of a researcher’s interest, a core database of reference
gene expression profiles for a large number small molecule
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compounds, and a similarity metric quantifying the close-
ness of the connection between the gene signature and
the reference profiles. Using a common “vocabulary” of
gene expression profiling [2], connectivity mapping allows
the establishment/discovery of connections between dif-
ferent biological states via their gene expression patterns
or characteristics, with great potential for application in
areas like predictive toxicity [3], candidate therapeutics
discovery and drugs repositioning [4,5]. The systematic
microarray experiments by the Broad Institute using dif-
ferent compounds, dosages, and cell lines led to the
accumulation of drug expression profiles and laid down
the foundation for subsequent data exploration and the
development of new frameworks. Following the intro-
duction of an improved connectivity mapping framework
featuring more principled statistical testing procedures
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and increased sensitivity [6], a standalone Java applica-
tion, sscMap, was developed and released implementing
this new algorithm [7], and later enabled with gene sig-
nature perturbation capability [8]. Given a user-supplied
query gene signature, sscMap calculates a connection
score between the query signature and each of the refer-
ence gene-expression profiles in the core database. The
program also computes similar scores for a large number
of randomly generated gene signatures, and compares the
observed score with the distribution of random scores to
obtain a p-value. The generation and processing of numer-
ous random signatures is the most time consuming part
of the computation, and causes a typical run of sscMap
on a standard desktop computer to take around ∼2h to
complete. Using a larger number of random signatures
can lead to more accurate estimations of p-values, but at
a cost of requiring overnight or over-weekend runs. Since
the computational costs will only increase as the number
of reference profiles in the database grows, the speed of
connectivity mapping will therefore soon become a lim-
iting factor to its wider application. On the other hand,
the tasks involved in connectivitymapping are particularly
amenable to parallel processing. This has the potential
to lead to a significant reduction in processing times
required, thereby not only expanding its capacity for wider
and novel applications in cancer research, but also allow-
ing a more accurate estimation of statistical significance
when desirable. In recent years, Graphics Processing Unit
(GPU) computing has enabled significant advances in sev-
eral bioinformatic research areas, eg, the MUMmerGPU
[9] which allows increased processing speeds in sequence
alignment, and CFMDS [10], a software platform for
fast dimensionality reduction of genome-scale data. Util-
ising NVIDIA’s parallel computing architecture CUDA
(Compute Unified Device Architecture) we sought to
advance the connectivity mapping capabilities by using
multiprocessor technology to harness localised, low cost
parallel computing.
Implementation
We installed the CUDA development toolkit on a selec-
tion of NVIDIA-enabled computers along with the
original sscMap software. These machines had various
operating systems and differing processing power coupled
with varying CUDA-enabled GPU cards. These cards have
different numbers of available programmable cores, rang-
ing from 8 to 448, allowing different numbers of threads
that may be run simultaneously (Table 1). This allows us
to demonstrate the speed and flexibility afforded by this
parallel architecture.
Design and algorithms
The key quantity in the connectivity mapping framework
is the connection score defined between a query gene
signature and a refset, i.e., a set of reference gene expres-
sion profiles. To evaluate the statistical significance of an
observed connection score, a p-value is calculated by com-
paring the observed score against the distribution of a
large number of random scores. These random scores are
obtained by generating a large number of random gene
signatures following the procedure described in [6], and
then calculating the connection score between the same
refset and each of the random gene signatures. Additional
file 1 provides a more detailed description of the algo-
rithm used in sscMap in the form of pseudocode. Because
the original sscMap handles all these tasks sequentially,
the large number of random gene signatures needed for
each p-value estimation lead to its long execution time.
cudaMap here tries to tackle this by parallelizing the pro-
cess and distributing this heavy computational load across
the multiple cores of the GPU device.
In the cudaMap application, 6100 reference profiles are
stored in a ‘ref-files’ folder, where each file contains a
drug-treated cell line with 22283 genes and their associ-
ated signed ranks. Query signature files, each containing
a list of gene identifiers (Affymetrix HG-U133A probe-
set IDs) and their corresponding flags to indicate up-
or down-regulation, were placed in a ‘queries’ folder. In
order to keep the memory footprint small cudaMap pro-
cesses queries sequentially, by reading them one at a time
and running through the reference profiles to measure
the scoring metrics for each reference against the query
signature. The GPU device is used to generate random sig-
natures of the same length as the original query signature
(using NVIDIA’s cuRAND random number generator).
Firstly we can generate a random gene signature of
length m using m random real numbers uniformly dis-
tributed between 0 and 1 as U[0, 1), and the algorithm to
achieve this is shown on page 3 of the Additional file 1. To
generate a large number, say Nrdsigs = 10000, of random
gene signatures of lengthm, we would (only) needmNrdsigs
randomnumbers withU[0, 1) distribution.Memory space
on the device for an array of mNrdsig real numbers is allo-
cated before a call to the cuRAND library to fill this array
with random numbers. The calculation of Nrdsigs random
scores is carried out on the CUDA device. The CUDA
kernel calls handle the vectorization on the device pri-
marily by the function “__global__ void computeRandom-
ConnectionScores(......)” to parallelize operations across
an allowable number of threads, to remove the bottlenecks
above. The key algorithms used in cudaMap are described
in Additional file 1.
Upon execution of the software through the command
terminal, users will be guided by selection choices in
respect to the analysis they wish to perform. The flexibil-
ity in user ref-files selection choices has been maintained
in the cudaMap version in order to allow users to create
metrics against individual drugs or distinct drug-cell-dose
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Table 1 Machines used in analysis
Machines and operating systems used in analysis GPUs associated with that machine
Optiplex 760 Core2 Duo E8500 and 4G of RAM (Windows XP) no GPU
Armari Magnetar with an Intel I7 processor and 24G of RAM (OpenSuse 12.1) Tesla C2050, Quadro FX380
Dell Lattitude E5400 with CPU P8700 with 4G of RAM (Windows XP) Geforce 9200M GS
Armari SM7046GT-TRF with an E5503 processor, 6G of RAM (Windows 7) Tesla C2050
Three of the four machines had CUDA capable devices and were tested with cudaMap against the sscMap software that ran on the CPU of those machines.
combinations. Here, users will be prompted to enter
their choice of reference-set characterisation, an expected
number of false positives to tolerate, and the number
of random signatures to generate for each p-value esti-
mation. Default parameters are set if the users wish to
proceed without modification, as is the case in the original
sscMap.
Analysis
We tested the software using gene signatures of increas-
ing size, ranging from a small random signature (n=10), to
intermediate and larger signatures that have been used in
describing sscMap previously, namely HDACs (n=25) and
Random02 (n=189). The latter two signatures are avail-
able in the original sscMap software and were used as
benchmarks for performance and significant compound
retrievals. We varied signature sizes in order to attain
differences in processing speeds based on the signature
and the random number generations required. We tested
the program against three CUDA-enabled machines with
varying GPU capabilities, with one machine having two
different GPU cards installed.
Results
To test the scalability of cudaMap, we ran it on several
systems with different processor specifications, operat-
ing systems and GPUs, comparing the results to that of
running sscMap. Figure 1 shows the outcome of run-
ning sscMap and cudaMap on an OpenSuse 12.1 Linux
machine with an Intel i7 processor and 24GB of RAM
and two GPU cards (Tesla C2050 and Quadro FX 380).
The gene signature used consisted of 10 gene identifiers.
The number of random gene signatures to generate for
each p-value estimation was varied to compare the per-
formances with increasing computational load. Figure 2
shows the processing times of running sscMap on the
CPUs of the four machines listed in Table 1. Three gene
signatures (with lengths n=10, 25, and 189 respectively)
were tested with the number of random gene signatures
per p-value set at 100 000. Figure 3 reports the pro-
cessing times for the same set of tasks, but run with
cudaMap on the three machines with GPU cards. As can
be seen from these figures, with the 10-gene signature and
100 000 random signature generations per p-value esti-
mation, the time taken to run sscMap on the Intel Core
Figure 1 sscMap and cudaMap processing times. Performance of cudaMap using two separate GPUs versus sscMap, running on the same
computer (Core i7) for increasing numbers of random signature generations. The signature length was 10 genes in all cases.
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Figure 2 sscMap processing times on different systems. Performance of sscMap on different test systems for three signature queries of lengths
189 (Random02), 25 (HDACs) and 10 (Random10). 100 000 random signature generations were used in all cases.
i7 processor was 57 minutes or 3387 seconds (the green
curve in Figure 1). For cudaMap, even the least powerful
test system, a laptop equipped with a Geforce 9200M GS
GPU, was able to reduce the processing time of a similar
task to 28 minutes or 1706 seconds (the first green bar in
Figure 3), demonstrating the effectiveness of paralleliza-
tion. Performance was greatly improved further by using
faster GPUs, such as the Quadro FX 380 and Tesla C2050
cards tested, both of which reduced processing times to
30–40 seconds (Figure 1) for the same task. Furthermore,
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Figure 3 cudaMap processing times on different systems. Performance of cudaMap on different test systems for three signature queries of
lengths 189 (Random02), 25 (HDACs) and 10 (Random10). 100 000 random signature generations were used in all cases.
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this improvement was maintained when up to 1 000 000
random signatures were generated per p-value (Figure 1).
Results returned from cudaMap for all signatures had
exact agreements with the sscMap results in terms of their
connection scores. In terms of their p-values, agreements
were achieved with regard to calls on statistical signifi-
cance in all cases, except a few borderlines around the
threshold p-value. Unlike the connection scores, exact
agreement between p-values are not expected due to the
way p-values were estimated, ie, by generation of random
numbers.
The results here showed dramatic speedups in perfor-
mance across all CUDA capable devices.
The quickest time was just over 30 seconds to perform
an analysis utilising the Tesla C2050 card, which repre-
sented a near 20x speed up over the sscMap software
running on the CPU of the same computer. The compari-
son of the two GPU cards on the samemachine also shows
the scalability of GPU computing, and in contrast to the i7
processor, suggests that using cudaMap to run a 10-gene
signature with the standard 100 000 random signature
generations did not tax either card too severely (the purple
and blue curves in Figure 1). Increasing beyond this point
(100 000 random signature generations), we start to see
the difference between the two GPU cards, although the
performance remained acceptable in both cases. sscMap,
which runs with the CPU, on the other hand, showed
dramatic increases in processing time to the point where
it would become unrealistic to run the analysis with a
large number of random signatures to generate. In general,
higher accuracy of p-value estimation is achieved when
more randomizations are used, which is feasible when
running cudaMap but may not be with sscMap because of
the computation time required.
Conclusions
The cudaMap software is open source and free to use with
parallel computation harnessing local GPUs. It carries out
gene expression connectivity mapping tasks in very fast
turnaround times with the functionality of running mul-
tiple signatures. Our tests demonstrated that cudaMap
even running on a laptop with a small compute capa-
bility (Geforce 9200M GPU) could outperform sscMap
running on a high-spec desktop computer such as the
Linux machine with an i7 CPU. In most cases and for
most signature sizes cudaMap performs under the 40 sec-
ond mark on this machine using its NVIDIA Tesla card, a
dramatic reduction in computing time compared to run-
ning sscMap on the same machine. With its capability
of fast gene expression connectivity mapping for robust
candidate therapeutics selection, cudaMap can serve as
a useful tool and resource in modern cancer research,
where high throughput ‘omics’ technologies are playing
indispensable roles. As the ‘omics’ datasets continue to
grow in their sizes and information content, each of these
datasets will, in turn, require more sophisticated analy-
sis and demandmore computing power. The development
of cudaMap represents an effort to meet the computa-
tional demands of a popular bioinformatic procedure in
biomedical research, namely gene expression connectivity
mapping to establish connections among genes, diseases
and drugs. We believe this accelerated software will be a
valuable tool and resource in many areas of biomedical
research including drug discovery, drug re-positioning,
and biological phenotypic targeting with small-molecule
compounds.
Availability and requirements
Project name: cudaMap
Project home page: http://purl.oclc.org/NET/cudaMap
Operating system(s):Windows and Linux
Programming language: C/C++/CUDA
Other requirements: CUDA 3.2 and above toolkit
License: Creative Commons license by-nc 3.0.
Any restrictions to use by non-academics: For commer-
cial use, please contact the authors
Additional file
Additional file 1: Pseudocode for the key algorithms used in sscMap
and cudaMap.
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